CD274 and adenocarcinoma: For example, in the KEYNOTE-059 Cohort 1 trial, patients with PD-L1-positive (CPS ≥ 1) G/GEJ adenocarcinoma who received pembrolizumab monotherapy showed significantly higher objective response rates (ORR) and improved overall survival (OS) compared to PD-L1-negative patients (CPS < 1) (12).